

# Pharma CapEx Market 2017 Share, Trend, Segmentation and Forecast to 2020

PharmSource - Bio/Pharma CapEx Trends 2016

PUNE, INDIA, January 17, 2017 /EINPresswire.com/ -- GET SAMPLE REPORT @

https://www.wiseguyreports.com/sam ple-request/839766-pharmsource-biopharma-capex-trends-2016

# **Summary**

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it's clear that bio/pharma companies would rather "make than buy."



According to the latest PharmSource Trend Report, <u>Bio/Pharma CapEx</u> Trends 2016, bio/pharma companies have invested over \$150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

#### Scope

- Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
- It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
- It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.

# Reasons to buy

- The 16-page report provides important insight that you won't find in any other source. This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Table of Content: Key Points
Executive Summary 1
Introduction 2
CapEx Overview 3
CapEx Relative to Other Financial Indicators 6

Nature of Capital Expenditure - What Is Being Built 8

What It Means 10

Appendix 12

Recently Announced and Completed Investments by Global Bio/Pharma Companies 12 Manufacturing Investments in Emerging Markets 2014-2021 by Global Bio/Pharma Companies

Selected CapEx Investments by Generic Companies 2014 Onwards 15

### List of Tables

Table 1 Composition of the PharmSource Universe

Table 2 Analysis of Identified CapEx Projects

Table 3 Location of Identified CapEx Projects

# List of Figures

Figure 1 CapEx by Company Sector 2015

Figure 2 Comparison of CapEx Change to Revenue Change 2010-2015

Figure 3 CapEx Trends at Bio/Pharma Companies 2010-2015

Figure 4 CapEx Spend and Growth Rate for Global Bio/Pharma Companies

Figure 5 Cash Spent on Dividends, Share Repurchase and CapEx by Selected US Global

Bio/Pharma Companies 2010-2015

Figure 6 Capital Expenditure for Leading Public CDMOs

ACCESS REPORT @ <a href="https://www.wiseguyreports.com/reports/839766-pharmsource-bio-pharma-capex-trends-2016">https://www.wiseguyreports.com/reports/839766-pharmsource-bio-pharma-capex-trends-2016</a>

### Related Reports:

PharmSource - Market Opportunities for Contract Manufacturers in Antibody Drug Conjugates PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2016 Edition

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2016 Edition

Entire Bundle Purchase @ 35% Discount Offer valid till 31 January

#### Get in touch:

LinkedIn: <a href="https://twitter.com/company/4828928">www.linkedin.com/company/4828928</a>
Twitter: <a href="https://twitter.com/WiseGuyReports">https://twitter.com/WiseGuyReports</a>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.